Access to the latest research — for scientists and people living with PD alike — in PDF's new scientific journal.
Impax Gets Approval For Parkinson's Drug - Generic Version of Sinemet CR
- May 17 2004
Impax Laboratories Inc. said Monday it got its sixth FDA drug approval this year for generic versions of Sinemet CR tablets, which is used to treat Parkinson's disease.
Sinemet is currently sold in the United States by Bristol-Myers Squibb. Hayward-based Impax will call its version of the drug Carbidopa/Levodopa Extended Release Tablets. The company said U.S. prescription sales of Sinemet CR and the one currently marketed generic equivalent were $126 million in the 12 months ended Feb. 29.
Parkinson's Disease is a progressive degenerative disease of the nerves.
Impax currently has 16 applications pending at the FDA, including five tentatively approved, which the company says address approximately $5.3 billion in U.S. market sales for the 12 months ended Feb. 29.
Source Date: May 17 2004
Source Publication: San Francisco Business Times, CA
View source URL